Mountain Crest Acquisition Corp. II

Status: Deal Closed
U=S+R R=S/10
IPO Proceeds, $M $57.50M
IPO Date Jan 8, 2021
CEO Suying Liu
Left Lead Chardan
IPO Cash in Trust 100.0%
SPAC Tenor 9+6
IPO Sector General

North America

IPO Geography US/Canada
Target Company Better Therapeutics
Deal Announced Apr 7, 2021
Deal Size, $M $184.00M
Deal Sector Healthcare
Deal Geography US/Canada
SEC Filings www.sec.gov
Approval Vote Oct 27, 2021
Amendment Vote TBD
Closing Date Oct 28, 2021
Formerly MCAD BTTX

Sign up for Free Trial

No credit card required

Sign in for more on Mountain Crest Acquisition Corp. II:

  • Structure and cap table
  • 5 directors & officers
  • 23 filings and events
  • 2 underwriters
  • 4 deal advisors
  • 2 legal advisors
Structure

Sign in to view structure, cap table, and calendar of events.

Team
Name Age Title
Suying Liu 32 Chairman and CEO
Dong Liu 35 CFO and Director
Nelson Haight 55 Director
Todd Milbourn 51 Director
Wenhau Zhang 50 Director

Sign in to view team biographies and more sponsor and affiliate data.

Advisors
Underwriters
Chardan BR 4,950,000 units
B. Riley FBR 50,000
5,000,000 units
Up-Front UW fee 2.00 %
Deferred UW fee 3.00 %

Sign in to view more advisor data.

Deal

Sign in to view merger details and deal financials.

Filings

Sign in to view 23 filings.

Shareholders

Sign in to view shareholders 13F filing data.